New insights into the pathogenesis and treatment of Waldenstrom macroglobulinemia

Current Opinion in Hematology

Volumn 18, Issue 4, 2011, Pages 260-265

  Issa, Ghayas C ^a   Leblebjian, Houry ^b   Roccaro, Aldo M ^a   Ghobrial, Irene M ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

microenvironment; novel agents; pathogenesis; treatment; Waldenstrom

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; ANGIOGENIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; BORTEZOMIB; CARFILZOMIB; CHLORAMBUCIL; CLADRIBINE; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ENZASTAURIN; EVEROLIMUS; FLUDARABINE; LENALIDOMIDE; MAMMALIAN TARGET OF RAPAMYCIN; MLN 2978; MYC PROTEIN; ONYX 0912; PERIFOSINE; POMALIDOMIDE; PROTEIN KINASE B; RAS PROTEIN; RETINOBLASTOMA PROTEIN; RITUXIMAB; SALINOSPORAMIDE A; STROMAL CELL DERIVED FACTOR 1; STROMAL CELL DERIVED FACTOR 1ALPHA; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN A;

ANEMIA; ANGIOGENESIS; CHROMOSOME 6Q; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CYTOPENIA; CYTOTOXICITY; DIARRHEA; DNA METHYLATION; EPIGENETICS; FUNCTIONAL PROTEOMICS; GENE; GENE REARRANGEMENT; HISTONE MODIFICATION; HUMAN; HYPOALBUMINEMIA; LARGE CELL TRANSFORMATION; LEUKEMIA; LUNG DISEASE; MULTICENTER STUDY (TOPIC); MYELODYSPLASTIC SYNDROME; NAUSEA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE; VH GENE; VOMITING; WALDENSTROEM MACROGLOBULINEMIA;

EPIGENOMICS; HUMANS; WALDENSTROM MACROGLOBULINEMIA;

EID: 79958845007     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3283474e5b     Document Type: Review

References (71)

1. Treon SP. How I treat Waldenstrom's macroglobulinemia. Blood 2009; 117:2918-2923.
2. Vijay A, Gertz MA. Waldenstrom macroglobulinemia. Blood 2007; 109: 5096-5103.
3. Waldenstrom J. Incipient myelomatosis or 'essential' hyperglobulinemia with fibrinogenopenia: a new syndrome? Acta Med Scand 1944; 117:216-247.
4. Treon SP, Dimopoulos M, Kyle RA. Defining Waldenstrom's macroglobulinemia. Semin Oncol 2003; 30:107-109. (Pubitemid 36506290)
5. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55:10-30.
6. Herrinton L, Weiss NS. Incidence of Waldenstrom's macroglobulinemia. Blood 1993; 82:3148-3150. (Pubitemid 23334943)
7. McMaster M. Familial Waldenstrom's macroglobulinemia. Semin Oncol 2003; 30:146-152. (Pubitemid 36506298)
8. Treon SP, Hunter ZR, Aggarwal A, et al. Characterization of familial Waldenstrom's macroglobulinemia. Ann Oncol 2006; 17:488-494.
9. Kyle RA, Therneau TM, Rajkumar SV, et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood 2003; 102: 3759-3764. (Pubitemid 37409398)
10. Royer RH, Koshiol J, Giambarresi TR, et al. Differential characteristics of Waldenstrom macroglobulinemia according to patterns of familial aggregation. Blood 2010; 115:4464-4471.
11. Ghobrial IM, Fonseca R, Gertz MA, et al. Prognostic model for diseasespecific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br J Haematol 2006; 133:158-164.
12. Kriangkum J, Taylor BJ, Treon SP, et al. Clonotypic IgM V/D/J sequence analysis in Waldenstrom macroglobulinemia suggests an unusual B-cell origin and an expansion of polyclonal B cells in peripheral blood. Blood 2004; 104:2134-2142. (Pubitemid 39297868)
13. Sahota S, Forconi F, Ottensmeier CH, et al. Typical Waldenstrom macroglobulinemia is derived from a B-cell arrested after cessation of somatic mutation but prior to isotype switch events. Blood 2002; 100:1505-1507. (Pubitemid 34864315)
14. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003; 30:110-115. (Pubitemid 36506291)
15. Remstein ED, Hanson CA, Kyle RA, et al. Despite apparent morphologic and immunophenotypic heterogeneity,Waldenstrom's macroglobulinemia is consistently composed of cells along a morphologic continuum of small lymphocytes, plasmacytoid lymphocytes, and plasma cells. Semin Oncol 2003; 30:182-186. (Pubitemid 36506306)
16. Hunter Z, Branagan AR, Manning R, et al. CD5, CD10, and CD23 expression in Waldenstrom's macroglobulinemia. Clin Lymphoma 2005; 5:246-249. (Pubitemid 40614235)
17. Schop RF, Kuehl WM, Van Wier SA, et al. Waldenstrom macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. Blood 2002; 100:2996-3001.
18. Schop RF, Jalal SM, Van Wier SA, et al. Deletions of 17p13.1 and 13q14 are uncommon in Waldenstrom macroglobulinemia clonal cells and mostly seen at the time of disease progression. Cancer Genet Cytogenet 2002; 132:55-60. (Pubitemid 34136052)
19. Terre C, Nguyen-Khac F, Barin C, et al. Trisomy 4, a new chromosomal abnormality in Waldenstrom's macroglobulinemia: a study of 39 cases. Leukemia 2006; 20:1634-1636. (Pubitemid 44264115)
20. Liu Y, Miyazawa K, Sashida G, et al. Deletion (20q) as the sole abnormality in Waldenstrom macroglobulinemia suggests distinct pathogenesis of 20q11 anomaly. Cancer Genet Cytogenet 2006; 169:69-72. (Pubitemid 44093733)
21. Turner CJ, Mack DH, Davis MM. Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin- secreting cells. Cell 1994; 77:297-306. (Pubitemid 24138626)
22. Wu Y, Bressette D, Carrell JA, et al. Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS. J Biol Chem 2000; 275:35478-35485.
23. Adamia S, Crainie M, Kriangkum J, et al. Abnormal expression of hyaluronan synthases in patients with Waldenstrom's macroglobulinemia. Semin Oncol 2003; 30:165-168. (Pubitemid 36506302)
24. Xu L, Leleu X, Hunter Z, et al. Abnormal expression of the plasma cell differentiation factor X-Box Protein 1 (Xbp-1) in Waldenstrom's macroglobulinemia [abstract]. Blood (ASH Annual Meeting Abstracts) 2005; 106: abstract 1003.
25. Chng WJ, Schop R, Price-Troska T, et al. Gene expression profiling of Waldenstrom's macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood 2006; 108: 2755-2763.
26. Gutierrez NC, Ocio EM, de Las Rivas J, et al. Gene expression profiling of B lymphocytes and plasma cells from Waldenstrom's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals. Leukemia 2007; 21:541-549.
27. Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358:1148-1159.
28. Esteller M. Epigenetics provides a new generation of oncogenes and tumoursuppressor genes. Br J Cancer 2007; 96 (Suppl):R26-R30.
29. Esteller M. Epigenetics provides a new generation of oncogenes and tumoursuppressor genes. Br J Cancer 2006; 94:179-183. (Pubitemid 43151531)
30. Cowland JB, Hother C, Gronbaek K. MicroRNAs and cancer. APMIS 2007; 115:1090-1106. (Pubitemid 350179476)
31. Hatjiharissi E, Ngo H, Leontovich A, et al. Proteomic analysis of Waldenstrom macroglobulinemia. Cancer Res 2007; 67:3777-3784. (Pubitemid 46762164)
32. Rosen N, She QB. AKT and cancer: is it all mTOR? Cancer Cell 2006; 10:254-256.
33. Yao D, Alexander CL, Quinn JA, et al. PTEN loss promotes rasHa-mediated papillomatogenesis via dual up-regulation of AKT activity and cell cycle deregulation but malignant conversion proceeds via PTEN-associated pathways. Cancer Res 2006; 66:1302-1312. (Pubitemid 43259908)
34. Li L, Ross AH. Why is PTEN an important tumor suppressor? J Cell Biochem 2007; 102:1368-1374. (Pubitemid 350223940)
35. Leleu X, Jia X, Runnels J, et al. The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood 2007; 110:4417-4426. (Pubitemid 351377808)
36. Roccaro AM, Sacco A, Husu EN, et al. Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. Blood 2010; 115:559-569.
37. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev 2004; 18:2195-2224.
38. Roccaro AM, Leleu X, Sacco A, et al. Dual targeting of the proteasome regulates survival and homing in Waldenstrom's macroglobulinemia. Blood 2008; 111:4752-4763.
39. Roccaro AM, Sacco A, Aujay M, et al. Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia. Blood 2010; 115:4051-4060.
40. Raaijmakers MH, Mukherjee S, Guo S, et al. Bone progenitor dysfunction inducesmyelodysplasia and secondary leukaemia.Nature 2010; 464:852-857.
41. Elsawa SF, Novak AJ, Grote DM, et al. B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom's macroglobulinemia. Blood 2005; 107:2882-2888.
42. MacKay F, Schneider P, Rennert P, Browning J. BAFF and APRIL: a tutorial on B cell survival. Annu Rev Immunol 2003; 21:231-264. (Pubitemid 37174532)
43. Hatzimichael E, Christou L, Bai M, et al. Serum levels of IL-6 and its soluble receptor (sIL-6R) in Waldenstrom's macroglobulinemia. Eur J Haematol 2001; 66:1-6. (Pubitemid 32099402)
44. Ngo H, Leleu X, Moreau AS, et al. Analysis of chemokine and adhesion markers in Waldenstrom macroglobulinemia [abstract]. Blood (ASH Annual Meeting Abstracts) 2006; 108:abstract 4653.
45. Tournilhac O, Santos DD, Xu L, et al. Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling. Ann Oncol 2006; 17:1275-1282. (Pubitemid 44288218)
46. Terpos E, Tasidou A, Kastritis E, et al. Angiogenesis in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma 2009; 9:46-49.
47. Anagnostopoulos A, Eleftherakis-Papaiakovou V, Kastritis E, et al. Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ration of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity. Br J Haematol 2007; 137:560-568. (Pubitemid 46817338)
48. Azab F, Azab A, Maiso P, et al. Eph-B2/Ephrin-B2 interaction plays a major role in the adhesion and survival of Waldenstrom macroglobulinemia cells in the context of the bone marrow microenvironment [abstract]. Blood (ASH Annual Meeting Abstracts), 2010; 116:abstract 142.
49. Ngo HT, Leleu X, Lee J, et al. SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia. Blood 2008; 112:150-158.
50. Ngo HT, Azab AK, Farag M, et al. Src tyrosine kinase regulates adhesion and chemotaxis in Waldenstrom macroglobulinemia. Clin Cancer Res 2009; 15:6035-6041.
51. Poulain S, Ertault M, Leleu X, et al. SDF1/CXCL12 (-801GA) polymorphism is a prognostic factor after treatment initiation in Waldenstrom macroglobulinemia. Leuk Res 2009; 33:1204-1207.
52. Ngo H, Hatjiharissi E, Leleu X, et al. The CXCR4/SDF-1 axis regulates migration and adhesion in Waldenstrom macroglobulinemia [abstract]. Blood (ASH Annual Meeting Abstracts) 2006; 108:abstract 2418.
53. Gertz MA. Waldenstrom macroglobulinemia: is newer really better? Leuk Lymphoma 2010; 51:2152-2153.
54. Leleu X, Soumerai J, Roccaro A, et al. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs. J Clin Oncol 2009; 27:250-255.
55. Rourke M, Anderson KC, Ghobrial IM. Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients. Leuk Lymphoma 2010; 51:1779-1792.
56. Dimopoulos MA, Tsatalas C, Zomas A, et al. Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone. Semin Oncol 2003; 30:265-269. (Pubitemid 36506323)
57. Dimopoulos MA, Gertz MA, Kastritis E, et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's macroglobulinemia. J Clin Oncol 2008; 27:120-126.
58. Treon SP, Soumerai JD, Branagan AR, et al. Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood 2008; 112:4452-4457.
59. Treon SP, Soumerai JD, Branagan AR, et al. Lenalidomide and rituximab in Waldenstrom's macroglobulinemia. Clin Cancer Res 2009; 15:355-360.
60. Gilardini A, Marmiroli P, Cavaletti G. Proteasome inhibition: a promising strategy for treating cancer, but what about neurotoxicity? Curr Med Chem 2008; 15:3025-3035.
61. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Treatment of relapsed or refractory Waldenstrom's macroglobulinemia with bortezomib. Haematologica 2005; 90:1655-1658. (Pubitemid 41814990)
62. Treon S, Hunter Z, Matous J, et al. Phase II study of bortezomib in Waldenstrom's macroglobulinemia: results of WMCTG trial 03-248 [abstract]. Blood (ASH Annual Meeting Abstracts) 2005; 106:abstract 490.
63. Chen CI, Kouroukis CT, White D, et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1570-1575. (Pubitemid 46733084)
64. Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab:WMCTG clinical trial 05-180. J Clin Oncol 2009; 27:3830-3835.
65. Ghobrial IM, Hong F, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010; 28:1422-1428.
66. Ghobrial IM, Xie W, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom macroglobulinemia. Am J Hematol 2010; 85:670-674.
67. Hideshima T, Catley L, Yasui H, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006; 107:4053-4062. (Pubitemid 43726814)
68. Ghobrial IM, Roccaro A, Hong F, et al. Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia. Clin Cancer Res 2010; 16:1033-1041.
69. Podar K, Raab MS, Zhang J, et al. Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). Blood 2006; 109:1669-1677. (Pubitemid 46239601)
70. Moreau AS, Jia X, Ngo HT, et al. Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia. Blood 2007; 109:4964-4972. (Pubitemid 46827795)
71. Ghobrial IM, Gertz M, Laplant B, et al. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol 2008; 28:1408-1414.